Protocol Ledger

NCT06706310 · Phase II · ACTIVE NOT RECRUITING

Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection

Interventional Phase II clinical trial protocol NCT06706310 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-04 Enrollment: 116 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06706310
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)116 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06706310
Protocol FieldVerified Registry Value
NCT IdentifierNCT06706310
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment116 participants (ACTUAL)
Registered Start Date2024-12-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI